Work

BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy

Year: 2011
Type: article
Abstract: The emergence of leukemia-specific cytotoxic T lymphocytes and their putative protective role against disease progression have recently been described in patients undergoing imatinib mesylate (IM) therapy, affected by either chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). 1 , 2 In particular, we have reported the immunological monitoring of 10 Ph + ALL patients during long-term IM maintenance treatment, demonstrating the inverse correlation between the frequencies of cytotoxic p190 BCR–ABL-specific T cells in the bone marrow (BM) and minimal residual disease (MRD) values. 2 Whether similar autologous p190 BCR–ABL-specific immune responses may be detectable and associated with the disease course under second-generation tyrosine-kinase inhibitors (TKIs), remains to be assessed.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W2047912975
FWCI: 0.533
Cites: 10
Cited by: 13
Related to: 9